32
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aims/hypothesis

          Lifestyle modification and weight loss are cornerstones of type 2 diabetes management. However, carbohydrate restriction may have weight-independent beneficial effects on glycaemic control. This has been difficult to demonstrate because low-carbohydrate diets readily decrease body weight. We hypothesised that carbohydrate restriction enhances the beneficial metabolic effects of weight loss in type 2 diabetes.

          Methods

          This open-label, parallel RCT included adults with type 2 diabetes, HbA 1c 48–97 mmol/mol (6.5–11%), BMI >25 kg/m 2, eGFR >30 ml min −1 [1.73 m] −2 and glucose-lowering therapy restricted to metformin or dipeptidyl peptidase-4 inhibitors. Participants were randomised by a third party and assigned to 6 weeks of energy restriction (all foods were provided) aiming at ~6% weight loss with either a carbohydrate-reduced high-protein diet (CRHP, percentage of total energy intake [E%]: CH30/P30/F40) or a conventional diabetes diet (CD, E%: CH50/P17/F33). Fasting blood samples, continuous glucose monitoring and magnetic resonance spectroscopy were used to assess glycaemic control, lipid metabolism and intrahepatic fat. Change in HbA 1c was the primary outcome; changes in circulating and intrahepatic triacylglycerol were secondary outcomes. Data were collected at Copenhagen University Hospital (Bispebjerg and Herlev).

          Results

          Seventy-two adults (CD 36, CRHP 36, all white, 38 male sex) with type 2 diabetes (mean duration 8 years, mean HbA 1c 57 mmol/mol [7.4%]) and mean BMI of 33 kg/m 2 were enrolled, of which 67 (CD 33, CRHP 34) completed the study. Body weight decreased by 5.8 kg (5.9%) in both groups after 6 weeks. Compared with the CD diet, the CRHP diet further reduced HbA 1c (mean [95% CI] −1.9 [−3.5, −0.3] mmol/mol [−0.18 (−0.32, −0.03)%], p = 0.018) and diurnal mean glucose (mean [95% CI] −0.8 [−1.2, −0.4] mmol/l, p < 0.001), stabilised glucose excursions by reducing glucose CV (mean [95% CI] −4.1 [−5.9, −2.2]%, p < 0.001), and augmented the reductions in fasting triacylglycerol concentration (by mean [95% CI] −18 [−29, −6]%, p < 0.01) and liver fat content (by mean [95% CI] −26 [−45, 0]%, p = 0.051). However, pancreatic fat content was decreased to a lesser extent by the CRHP than the CD diet (mean [95% CI] 33 [7, 65]%, p = 0.010). Fasting glucose, insulin, HOMA2-IR and cholesterol concentrations (total, LDL and HDL) were reduced significantly and similarly by both diets.

          Conclusions/interpretation

          Moderate carbohydrate restriction for 6 weeks modestly improved glycaemic control, and decreased circulating and intrahepatic triacylglycerol levels beyond the effects of weight loss itself compared with a CD diet in individuals with type 2 diabetes. Concurrent differences in protein and fat intakes, and the quality of dietary macronutrients, may have contributed to these results and should be explored in future studies.

          Trial registration

          ClinicalTrials.gov NCT03814694.

          Funding

          The study was funded by Arla Foods amba, The Danish Dairy Research Foundation, and Copenhagen University Hospital Bispebjerg Frederiksberg.

          Graphical abstract

          Supplementary Information

          The online version contains peer-reviewed but unedited supplementary material available at 10.1007/s00125-021-05628-8.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          International physical activity questionnaire: 12-country reliability and validity.

          Physical inactivity is a global concern, but diverse physical activity measures in use prevent international comparisons. The International Physical Activity Questionnaire (IPAQ) was developed as an instrument for cross-national monitoring of physical activity and inactivity. Between 1997 and 1998, an International Consensus Group developed four long and four short forms of the IPAQ instruments (administered by telephone interview or self-administration, with two alternate reference periods, either the "last 7 d" or a "usual week" of recalled physical activity). During 2000, 14 centers from 12 countries collected reliability and/or validity data on at least two of the eight IPAQ instruments. Test-retest repeatability was assessed within the same week. Concurrent (inter-method) validity was assessed at the same administration, and criterion IPAQ validity was assessed against the CSA (now MTI) accelerometer. Spearman's correlation coefficients are reported, based on the total reported physical activity. Overall, the IPAQ questionnaires produced repeatable data (Spearman's rho clustered around 0.8), with comparable data from short and long forms. Criterion validity had a median rho of about 0.30, which was comparable to most other self-report validation studies. The "usual week" and "last 7 d" reference periods performed similarly, and the reliability of telephone administration was similar to the self-administered mode. The IPAQ instruments have acceptable measurement properties, at least as good as other established self-reports. Considering the diverse samples in this study, IPAQ has reasonable measurement properties for monitoring population levels of physical activity among 18- to 65-yr-old adults in diverse settings. The short IPAQ form "last 7 d recall" is recommended for national monitoring and the long form for research requiring more detailed assessment.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

            Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.

              Glucose metabolism is normally regulated by a feedback loop including islet β cells and insulin-sensitive tissues, in which tissue sensitivity to insulin affects magnitude of β-cell response. If insulin resistance is present, β cells maintain normal glucose tolerance by increasing insulin output. Only when β cells cannot release sufficient insulin in the presence of insulin resistance do glucose concentrations rise. Although β-cell dysfunction has a clear genetic component, environmental changes play an essential part. Modern research approaches have helped to establish the important role that hexoses, aminoacids, and fatty acids have in insulin resistance and β-cell dysfunction, and the potential role of changes in the microbiome. Several new approaches for treatment have been developed, but more effective therapies to slow progressive loss of β-cell function are needed. Recent findings from clinical trials provide important information about methods to prevent and treat type 2 diabetes and some of the adverse effects of these interventions. However, additional long-term studies of drugs and bariatric surgery are needed to identify new ways to prevent and treat type 2 diabetes and thereby reduce the harmful effects of this disease. Copyright © 2014 Elsevier Ltd. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                mads.norvin.thomsen@regionh.dk
                Journal
                Diabetologia
                Diabetologia
                Diabetologia
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0012-186X
                1432-0428
                7 January 2022
                : 1-12
                Affiliations
                [1 ]GRID grid.411702.1, ISNI 0000 0000 9350 8874, Department of Endocrinology, , Copenhagen University Hospital Bispebjerg, ; Copenhagen, Denmark
                [2 ]GRID grid.5254.6, ISNI 0000 0001 0674 042X, Department of Nutrition, Exercise and Sports, , University of Copenhagen, ; Copenhagen, Denmark
                [3 ]GRID grid.411900.d, ISNI 0000 0004 0646 8325, Department of Radiology, , Copenhagen University Hospital Herlev, ; Copenhagen, Denmark
                [4 ]GRID grid.411905.8, ISNI 0000 0004 0646 8202, Department of Clinical Biochemistry, , Copenhagen University Hospital Hvidovre, ; Copenhagen, Denmark
                [5 ]GRID grid.7143.1, ISNI 0000 0004 0512 5013, Department of Endocrinology, , Odense University Hospital, ; Odense, Denmark
                [6 ]GRID grid.7048.b, ISNI 0000 0001 1956 2722, Department of Clinical Medicine, , Aarhus University, ; Aarhus, Denmark
                [7 ]GRID grid.5254.6, ISNI 0000 0001 0674 042X, Novo Nordisk Foundation Center for Basic Metabolic Research, , University of Copenhagen, ; Copenhagen, Denmark
                [8 ]GRID grid.5254.6, ISNI 0000 0001 0674 042X, Department of Biomedical Sciences, , University of Copenhagen, ; Copenhagen, Denmark
                [9 ]GRID grid.411905.8, ISNI 0000 0004 0646 8202, Department of Endocrinology, , Copenhagen University Hospital Hvidovre, ; Copenhagen, Denmark
                Author information
                http://orcid.org/0000-0002-3821-320X
                https://orcid.org/0000-0001-6607-2064
                https://orcid.org/0000-0002-2742-3893
                https://orcid.org/0000-0001-8968-8996
                https://orcid.org/0000-0001-8952-8394
                https://orcid.org/0000-0002-5379-0961
                https://orcid.org/0000-0001-8509-2036
                https://orcid.org/0000-0001-6853-3805
                https://orcid.org/0000-0001-7621-3131
                https://orcid.org/0000-0002-5017-1815
                https://orcid.org/0000-0002-1312-7364
                https://orcid.org/0000-0002-2409-9725
                https://orcid.org/0000-0002-6827-7036
                https://orcid.org/0000-0002-9152-0583
                Article
                5628
                10.1007/s00125-021-05628-8
                8739348
                34993571
                0b4711b0-31b6-4a23-8352-06d897e25b4b
                © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 25 May 2021
                : 29 September 2021
                Funding
                Funded by: Arla Foods amba
                Funded by: The Danish Dairy Research Foundation
                Funded by: Copenhagen University Hospital Bispebjerg Frederiksberg
                Categories
                Article

                Endocrinology & Diabetes
                carbohydrate restriction,dietary intervention,dyslipidaemia,glycaemic control,low-energy diet,non-alcoholic fatty liver disease,nutritional therapy,obesity,type 2 diabetes mellitus,weight loss

                Comments

                Comment on this article